Compare Natera Inc. Common Stock (NTRA) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Block Inc — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Block Inc trades at $75.39 (market cap $46.18B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Block Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Block Inc for 78 Days on average.
| NTRA | XYZ | |
|---|---|---|
Market Cap | $57.03B | $46.18B |
Volume | 1,131,157 | 4,211,951 |
Sector | Health | Technology |
52-Week High | $425.64 | $84.85 |
52-Week Low | $179.42 | $49.04 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $56.18B | $41.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
XYZ trades at $75.87, down 1.21% today, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, though net income margin is thin at 1.43%. The company shows robust revenue growth, reaching $24.19B in 2025, and is expanding through partnerships like Apple and Workday. Cash flow from operations is strong at $2.58B, but net cash flow was negative $749M in 2025 due to heavy investing.
Outlook is positive with a consensus price target of $97.47, implying 28% upside. Key opportunities include continued earnings beats and strategic expansions, but risks include high P/E of 137.25, insider selling, and competitive pressures in fintech. The stock's valuation relies on sustained growth execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
